C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Neuroscience

• Publication date

  2015-07-29

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1523/JNEUROSCI.0387-15.2015PMID 26224867PMCID PMC6605107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human secreted tau increases amyloid-beta production.

  2015cited by this paper
• Tau immunization: a cautionary tale?

  2015cited by this paper
• Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target*

  2014cited by this paper
• Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies.

  2014influential reference
• Comparison and Optimization of hiPSC Forebrain Cortical Differentiation Protocols

  2014cited by this paper
• Specificity of Anti-Tau Antibodies when Analyzing Mice Models of Alzheimer's Disease: Problems and Solutions

  2014cited by this paper
• Proteopathic tau seeding predicts tauopathy in vivo

  2014influential reference
• The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

  2014cited by this paper
• The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.

  2014cited by this paper
• Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

  2014influential reference
• Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity*

  2014cited by this paper
• Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

  2014cited by this paper
• Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation.

  2013cited by this paper
• The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms

  2013cited by this paper
• Physiological release of endogenous tau is stimulated by neuronal activity

  2013influential reference
• Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

  2013cited by this paper
• Tau pathology and neurodegeneration.

  2013cited by this paper
• Dynamics of hippocampal neurogenesis in adult humans.

  2013cited by this paper
• Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

  2013cited by this paper
• Spreading of tau pathology in Alzheimer's disease by cell‐to‐cell transmission

  2013cited by this paper
• Trans-cellular Propagation of Tau Aggregation by Fibrillar Species*

  2012influential reference
• Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles

  2012influential reference
• Constitutive secretion of tau protein by an unconventional mechanism.

  2012influential reference
• Tau and tauopathies.

  2012influential reference
• Hyperphosphorylation and Cleavage at D421 Enhance Tau Secretion

  2012influential reference
• Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?

  2012cited by this paper
• Propagation of tau pathology in a model of early Alzheimer's disease.

  2012cited by this paper
• Detection of tau forms in CSF requires sensitive techniques

  2012cited by this paper
• Extracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with Tauopathies*

  2012influential reference
• Biochemistry and cell biology of tau protein in neurofibrillary degeneration.

  2012cited by this paper
• S3‐03‐05: Transmission and Spreading of Tauopathy in Transgenic Mouse Brain

  2011cited by this paper
• Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease*

  2011influential reference
• Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles*

  2011cited by this paper
• Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites

  2011cited by this paper
• Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers

  2011influential reference
• Immunotherapy for Tauopathies

  2011cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Specification of Region-Specific Neurons Including Forebrain Glutamatergic Neurons from Human Induced Pluripotent Stem Cells

  2010cited by this paper
• Secretion of human tau fragments resembling CSF‐tau in Alzheimer's disease is modulated by the presence of the exon 2 insert

  2010influential reference
• Interneuronal Transfer of Human Tau Between Lamprey Central Neurons in situ

  2010influential reference
• Transmission and spreading of tauopathy in transgenic mouse brain

  2009cited by this paper
• A facile method for expression and purification of the Alzheimer’s disease-associated amyloid β-peptide

  2009cited by this paper
• gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons.

  2009influential reference
• Propagation of Tau Misfolding from the Outside to the Inside of a Cell*

  2009influential reference
• Characterization of tau in cerebrospinal fluid using mass spectrometry.

  2008cited by this paper
• Assessment of Cell Viability in Primary Neuronal Cultures

  2008cited by this paper
• Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids

  2006influential reference
• Solution state characterization of amyloid beta-derived diffusible ligands.

  2006cited by this paper
• Solution State Characterization of Amyloid β-Derived Diffusible Ligands

  2006cited by this paper
• Culturing hippocampal neurons

  2006influential reference
• Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro.

  2005cited by this paper
• The Formation of Straight and Twisted Filaments from Short Tau Peptides*

  2004cited by this paper
• Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain.

  2004cited by this paper
• Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus

  2002cited by this paper
• Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

  2002cited by this paper
• Assessment of Cell Viability

  2001cited by this paper
• Assessment of Cell Viability in Primary Neuronal Cultures

  2000cited by this paper
• Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke

  2000cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998influential reference
• The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments

  1997influential reference
• Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay*

  1996cited by this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper

• Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias

  2026cites this paper
• Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease

  2026cites this paper
• The interplay between autophagy and unconventional secretion in neurodegeneration.

  2026cites this paper
• ApoE-calypse tau: ApoE-tau synergy in Alzheimer's disease.

  2025cites this paper
• Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease

  2025cites this paper
• LC3-associated endocytosis facilitates extracellular Tau aggregate internalization and degradation in microglia

  2025cites this paper
• Influence of cognitive impairment and race on plasma p‐Tau217 in two diverse cohorts

  2025cites this paper
• Synaptotoxic effects of extracellular tau are mediated by its microtubule-binding region

  2025cites this paper
• A novel C. elegans model for MAPT/Tau spreading reveals genes critical for endolysosomal integrity and seeded MAPT/Tau aggregation

  2025cites this paper
• Targeting of phosphorylated tau at threonine 181 by a Qβ virus‐like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques

  2025cites this paper
• A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

  2025cites this paper
• Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases

  2025cites this paper
• Neuron-derived extracellular vesicle-based diagnostics for Tau and Alzheimer’s disease

  2025cites this paper
• Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates

  2024cites this paper
• Novel avenues of tau research

  2024cites this paper
• Pilot Study of the Total and Phosphorylated Tau Proteins in Early-Stage Multiple Sclerosis

  2024cites this paper
• Intracellular dynamics of ubiquitin-like 3 visualized using an inducible fluorescent timer expression system

  2024cites this paper
• Clearance of beta-amyloid and tau aggregates is size dependent and altered by an inflammatory challenge

  2024cites this paper
• Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses

  2024cites this paper
• The Adult Neurogenesis Theory of Alzheimer’s Disease

  2023cites this paper
• Extracellular Tau Oligomers Damage the Axon Initial Segment

  2023cites this paper
• Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations

  2023cites this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cites this paper
• Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review

  2023cites this paper
• Traumatic brain injury and the pathways to cerebral tau accumulation

  2023cites this paper
• Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia

  2023cites this paper
• Frontotemporal lobar degeneration

  2023cites this paper
• The emerging double-edged sword role of exosomes in Alzheimer’s disease

  2023cites this paper
• Chronic nSMase inhibition suppresses neuronal exosome spreading and sex-specifically attenuates amyloid pathology in APP knock-in Alzheimer’s disease mice

  2023cites this paper
• Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.

  2023cites this paper
• Alzheimer's disease brain‐derived extracellular vesicles reveal altered synapse‐related proteome and induce cognitive impairment in mice

  2023cites this paper
• Unconventional secretion of tau by VAMP8 impacts its intra- and extracellular cleavage

  2022influential citation
• A call for better understanding of target engagement in Tau antibody development.

  2022cites this paper
• COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences

  2022cites this paper
• Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint

  2022cites this paper
• Heparan Sulfate Proteoglycans (HSPGs) Serve as the Mediator Between Monomeric Tau and Its Subsequent Intracellular ERK1/2 Pathway Activation

  2022cites this paper
• Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

  2022cites this paper
• The emerging role of autophagy and mitophagy in tauopathies: From pathogenesis to translational implications in Alzheimer’s disease

  2022cites this paper
• Neurophysiological effects of human-derived pathological tau conformers in the APPKM670/671NL.PS1/L166P amyloid mouse model of Alzheimer’s disease

  2022cites this paper
• Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice

  2021cites this paper
• Central Nervous System Cell-Derived Exosomes in Neurodegenerative Diseases

  2021cites this paper
• Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders

  2021cites this paper
• The propagation mechanisms of extracellular tau in Alzheimer’s disease

  2021cites this paper
• The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies

  2021cites this paper
• Opposing functions for retromer and Rab11 in extracellular vesicle traffic at presynaptic terminals

  2021cites this paper
• The Association between Tau Protein Level in Cerebrospinal Fluid and Cognitive Status: A Large-Scale Analysis of GAAIN Database

  2021cites this paper
• Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

  2021influential citation
• Microtubule-modulating Agents in the Fight Against Neurodegeneration: Will it ever Work?

  2021cites this paper
• Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P‐tau181, P‐tau217 and P‐tau231 assays

  2021cites this paper
• NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression

  2021cites this paper
• Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

  2021cites this paper
• Intracellular Responses of Glial Cells To Monomeric Tau Protein Are Closely Mediated By Heparan Sulfate Proteoglycans (HSPGs)

  2021cites this paper
• Synaptic tau: A pathological or physiological phenomenon?

  2021cites this paper
• Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays

  2021cites this paper
• Exosomal tau with seeding activity is released from Alzheimer’s disease synapses, and seeding potential is associated with amyloid beta

  2021cites this paper
• Exosomes: Potential Disease Biomarkers and New Therapeutic Targets

  2021cites this paper
• Biomarker potential of brain‐secreted extracellular vesicles in blood in Alzheimer's disease

  2020cites this paper
• Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake

  2020influential citation
• Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes

  2020cites this paper
• Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid

  2020cites this paper
• Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease

  2020cites this paper
• Viral Delivery of Non-Mutated Human Truncated Tau to Neurons Recapitulates Key Features of Human Tauopathy in Wild-Type Mice

  2020cites this paper
• Plasma Biomarker for Post-concussive Syndrome: A Pilot Study Using an Alternating Current Electro-Kinetic Platform

  2020cites this paper
• Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease

  2020cites this paper
• Dangerous Liaisons: Tau Interaction with Muscarinic Receptors

  2020cites this paper
• The interplay between aging‐associated loss of protein homeostasis and extracellular vesicles in neurodegeneration

  2020cites this paper
• How to face the aging world – lessons from dementia research

  2020cites this paper
• Alzheimer’s disease: phenotypic approaches using disease models and the targeting of tau protein

  2020cites this paper
• Amyloid β-protein and beyond: the path forward in Alzheimer's disease.

  2020cites this paper
• N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach.

  2020cites this paper
• TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading

  2020cites this paper
• Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models

  2020cites this paper
• Differences Between Human and Murine Tau at the N-terminal End

  2020cites this paper
• Tau in the brain interstitial fluid is fragmented and seeding-competent

  2020cites this paper
• Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

  2020cites this paper
• Extracellular Vesicles in Alzheimer’s and Parkinson’s Disease: Small Entities with Large Consequences

  2020cites this paper
• Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

  2020cites this paper
• Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase

  2019cites this paper
• Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review

  2019cites this paper
• Minimalistic in vitro systems for investigating tau pathology.

  2019cites this paper
• A walk through tau therapeutic strategies

  2019cites this paper
• Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein

  2019cites this paper
• Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved

  2019cites this paper
• Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer’s Disease

  2019cites this paper
• Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease

  2019cites this paper
• Opposing functions for retromer and Rab11 in extracellular vesicle cargo traffic at presynaptic terminals

  2019cites this paper
• Loss of the Alzheimer’s-linked bridging integrator 1 (BIN1) protein affects synaptic structure and disrupts tau localisation and release

  2019cites this paper
• Four-repeat tauopathies.

  2019cites this paper
• Tau Secretion: Good and Bad for Neurons

  2019cites this paper
• Propagation of Tau via Extracellular Vesicles

  2019cites this paper
• Fab/epitope complex of mouse monoclonal antibody 8B2 targeting a non-phosphorylated tau epitope.

  2019cites this paper
• Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology

  2019cites this paper
• Post-translational modification and protein sorting to small extracellular vesicles including exosomes by ubiquitin and UBLs

  2019cites this paper
• Normal and Pathological Tau Uptake Mediated by M1/M3 Muscarinic Receptors Promotes Opposite Neuronal Changes

  2019cites this paper
• Tau fragments: role as biomarkers and in the pathogenesis of Alzheimer's disease and other tauopathies

  2019cites this paper
• Advances and considerations in AD tau-targeted immunotherapy

  2019cites this paper
• PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins

  2019cites this paper
• Tau Secretion.

  2019cites this paper
• Tau Prion-Like Propagation: State of the Art and Current Challenges.

  2019cites this paper
• AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy

  2018cites this paper